



## ROLE OF PHARMACOGENOMICS IN PERSONALIZED MEDICATION THERAPY FOR PATIENTS IN NURSING CARE

Rahmah Murghil Alaqas Alruwaili<sup>1\*</sup>, Thuraya Mohammed Alanzi<sup>2</sup>, Norah Nazal D Alshammari<sup>3</sup>, Jamal Alnaqdi Saddah Alruwaili<sup>4</sup>, Maryam Sufuq Alanazi<sup>5</sup>, Abdulrazaq Hamoud Alruwaili<sup>6</sup>, Haitham Hael Muhawwis Alshammari<sup>7</sup>, Khaled Bandar Mohsen Al Otaibi<sup>8</sup>, Alruwaili Farhan Nafea L<sup>9</sup>, Fadiyah Salem Sakhani Alruwaili<sup>10</sup>

### Abstract:

Pharmacogenomics plays a crucial role in personalized medication therapy for patients in nursing care by tailoring drug treatments based on an individual's genetic makeup. This review article explores the significance of pharmacogenomics in optimizing medication therapy for patients in nursing care settings. The integration of pharmacogenomic testing into clinical practice has the potential to enhance treatment outcomes, minimize adverse drug reactions, and improve patient safety. By identifying genetic variations that influence drug response, healthcare providers can make informed decisions regarding drug selection, dosing, and monitoring, leading to more effective and personalized patient care. This article discusses the current state of pharmacogenomics research, its applications in nursing care, challenges in implementation, and future directions in the field.

**Keywords:** Pharmacogenomics, Personalized medicine, Medication therapy, Nursing care, Genetic variations, Patient safety

<sup>1</sup> \*Nursing Specialist, North Medical Tower at Arar, Saudi Arabia

<sup>2</sup> Nursing technician, Prince Abdulaziz bin Musaed Hospital, Arar, Saudi Arabia.

<sup>3</sup> Nursing technician, Hafar Al-Batin Health Cluster, Saudi Arabia.

<sup>4</sup> Technician-Nursing, Al Jawhara Health Center in Arar, Saudi Arabia.

<sup>5</sup> Nursing Technician, Al-Rabwa Health Center, Arar City, Saudi Arabia.

<sup>6</sup> pharmacy technician, Turaif General Hospital, Saudi Arabia.

<sup>7</sup> Pharmacy technician, Rafha Central Hospital, Saudi Arabia.

<sup>8</sup> Pharmacy technician, Dawademi general hospital, Saudi Arabia.

<sup>9</sup> Pharmacy technician, Prince Abdulaziz bin Musaed Hospital, Arar, Saudi Arabia.

<sup>10</sup> Pharmacy technician, Directorate of Health Affairs in the Northern Border Region, Saudi Arabia.

**\*Corresponding Author:** Rahmah Murghil Alaqas Alruwaili

\*Nursing Specialist, North Medical Tower at Arar, Saudi Arabia

**DOI:** 10.53555/ecb/2022.11.8.125

**Introduction:**

Pharmacogenomics, a relatively new field in healthcare, is revolutionizing the way medications are prescribed and administered to patients. By studying how an individual's genetic makeup influences their response to drugs, healthcare providers are able to tailor medication therapy to each patient's unique genetic profile. This personalized approach, known as pharmacogenomics, has the potential to greatly improve patient outcomes and reduce the risk of adverse drug reactions [1].

In nursing care, pharmacogenomics plays a crucial role in ensuring that patients receive the most effective and safe treatment possible. By analyzing a patient's genetic information, nurses can identify genetic variations that may impact how a patient metabolizes certain medications. This information can help nurses determine the most appropriate dosage of a medication, or even identify alternative medications that may be more effective for a particular patient [2].

One of the key benefits of pharmacogenomics in nursing care is the ability to predict how a patient will respond to a medication before it is administered. This can help prevent adverse drug reactions, which are a common cause of hospitalizations and even death among patients. By using pharmacogenomic testing, nurses can identify patients who are at risk for adverse reactions to certain medications and adjust their treatment plan accordingly [3].

Another important aspect of pharmacogenomics in nursing care is the potential for more effective pain management. Pain is a common symptom among patients in nursing care, and finding the right medication and dosage to effectively manage pain can be challenging. By using pharmacogenomic testing, nurses can identify which pain medications are most likely to be effective for a particular patient, leading to better pain management outcomes [4].

In addition to improving patient outcomes, pharmacogenomics can also help reduce healthcare costs. Adverse drug reactions and ineffective medications can lead to unnecessary hospitalizations and additional medical expenses. By using pharmacogenomic testing to personalize medication therapy, nurses can help reduce the risk of adverse reactions and ensure that patients are receiving the most effective treatment, ultimately leading to cost savings for both patients and healthcare systems [5].

Despite the many benefits of pharmacogenomics in nursing care, there are still challenges that need to be addressed. One of the main challenges is the cost of pharmacogenomic testing, which can be

prohibitive for some patients and healthcare providers. Additionally, there is a need for more education and training for nurses on how to interpret and use pharmacogenomic information in patient care [6].

**Genetic Basis of Drug Response Variability:**

The field of pharmacogenomics has made significant strides in recent years in understanding the genetic basis of drug response variability. It is now widely recognized that genetic factors play a crucial role in determining how individuals respond to drugs, including both their efficacy and potential side effects. This variability in drug response can have profound implications for patient care, as it can influence the effectiveness of treatment and the likelihood of adverse reactions [7].

**Genetic Factors Influencing Drug Response**

There are several genetic factors that can influence how individuals respond to drugs. One of the most well-studied factors is variation in drug-metabolizing enzymes, which play a key role in the metabolism and elimination of drugs from the body. Genetic variations in these enzymes can affect how quickly or slowly a drug is metabolized, leading to differences in drug levels in the body and ultimately in drug response [8].

Another important genetic factor is variation in drug targets, such as receptors or enzymes that are the intended targets of a drug. Genetic variations in these targets can affect how well a drug binds to its target and exerts its therapeutic effects. For example, variations in the gene encoding the beta-adrenergic receptor can influence how individuals respond to beta-blocker drugs used to treat hypertension and heart disease [9].

In addition to variations in drug-metabolizing enzymes and drug targets, genetic variations in drug transporters, which help move drugs in and out of cells, can also influence drug response. Variations in these transporters can affect how much of a drug reaches its intended target inside cells, leading to differences in drug efficacy [10].

**Mechanisms of Genetic Influence on Drug Response**

The mechanisms by which genetic variations influence drug response are complex and can vary depending on the drug and the specific genetic variant involved. One common mechanism is through alterations in drug metabolism, where genetic variations in drug-metabolizing enzymes can lead to changes in the rate at which a drug is broken down and eliminated from the body. This can result in differences in drug levels in the body, affecting both drug efficacy and toxicity [11].

Genetic variations can also influence drug response by altering drug targets, such as receptors or enzymes that are the intended targets of a drug. Variations in these targets can affect how well a drug binds to its target and exerts its therapeutic effects. For example, a genetic variant that leads to decreased expression of a drug target may result in reduced drug efficacy [12].

#### Implications for Personalized Medicine

Understanding the genetic basis of drug response variability has important implications for personalized medicine, which aims to tailor medical treatment to individual genetic profiles. By identifying genetic variants that influence drug response, healthcare providers can make more informed decisions about drug selection and dosing, leading to improved treatment outcomes and reduced risk of adverse reactions [13].

One of the key goals of personalized medicine is to use genetic information to predict how individuals will respond to a particular drug, allowing for more precise and effective treatment. For example, genetic testing for variations in drug-metabolizing enzymes can help identify individuals who are at increased risk of adverse reactions to certain drugs due to poor metabolism. This information can then be used to adjust drug dosing or select alternative medications that are better tolerated [14].

The genetic basis of drug response variability is a complex and multifaceted field that has important implications for patient care. By understanding how genetic variations influence drug response, healthcare providers can optimize treatment strategies and improve patient outcomes. Continued research in this area will further our understanding of the genetic basis of drug response variability and pave the way for more personalized and effective medical treatments [15].

#### Clinical Applications of Pharmacogenomics in Medication Therapy:

Pharmacogenomics is a field of study that focuses on how an individual's genetic makeup influences their response to medications. It combines the disciplines of pharmacology and genomics to develop personalized medicine strategies. By analyzing a patient's genetic profile, healthcare providers can tailor medication therapy to maximize efficacy and minimize adverse effects. This approach, known as pharmacogenomics, has the potential to revolutionize the way medications are prescribed and administered [16].

One of the key clinical applications of pharmacogenomics is in medication therapy. Traditionally, medications are prescribed based on a one-size-fits-all approach, with little

consideration for individual genetic differences. However, research has shown that genetic variations can significantly impact how a patient metabolizes and responds to certain drugs. By incorporating pharmacogenomic testing into clinical practice, healthcare providers can identify these genetic variations and adjust medication therapy accordingly [17].

For example, certain genetic variations can affect how the body metabolizes the blood thinner warfarin. Patients with these variations may require higher or lower doses of the medication to achieve the desired therapeutic effect. By conducting pharmacogenomic testing before prescribing warfarin, healthcare providers can determine the most appropriate dose for each patient, reducing the risk of over- or under-dosing [18].

Another example is the drug clopidogrel, which is commonly prescribed to prevent blood clots in patients with cardiovascular disease. However, some patients have genetic variations that make them less responsive to clopidogrel, increasing their risk of heart attacks or strokes. Pharmacogenomic testing can identify these patients before they start taking the medication, allowing healthcare providers to explore alternative treatment options or adjust the dose of clopidogrel to improve its effectiveness [19].

In addition to optimizing medication therapy, pharmacogenomics can also help reduce the incidence of adverse drug reactions. Adverse drug reactions are a significant cause of morbidity and mortality, and they are often linked to genetic variations that affect how a patient metabolizes certain medications. By identifying these genetic variations through pharmacogenomic testing, healthcare providers can avoid prescribing medications that are likely to cause adverse reactions in a particular patient [20].

Furthermore, pharmacogenomics can improve medication adherence and patient outcomes. When patients experience fewer side effects and better therapeutic outcomes with their medications, they are more likely to adhere to their treatment regimens. This can lead to better disease management, improved quality of life, and reduced healthcare costs in the long run [21].

Overall, the clinical applications of pharmacogenomics in medication therapy have the potential to revolutionize the way healthcare is delivered. By incorporating genetic information into medication prescribing practices, healthcare providers can personalize treatment plans to better meet the needs of individual patients. This personalized approach can lead to improved therapeutic outcomes, reduced adverse drug reactions, and enhanced patient adherence. As

pharmacogenomics continues to advance, it is likely to play an increasingly important role in shaping the future of medicine [22].

### **Implementation Challenges in Nursing Care Settings:**

Nursing care settings play a crucial role in providing quality healthcare to patients. Nurses are at the forefront of patient care, and they are responsible for implementing care plans, administering medications, monitoring patients' conditions, and providing emotional support to patients and their families. However, despite the importance of nursing care settings, there are several implementation challenges that nurses face on a daily basis [1].

One of the biggest challenges in nursing care settings is staffing shortages. The demand for nurses continues to rise due to an aging population, increased prevalence of chronic diseases, and advancements in medical technology. However, there is a shortage of nurses entering the workforce to meet this growing demand. This shortage puts a strain on nurses who are already working in healthcare settings, leading to increased workloads, burnout, and decreased job satisfaction [18].

Another challenge in nursing care settings is the lack of resources and support. Nurses often have to work with limited resources, such as inadequate staffing, outdated equipment, and insufficient training. This can hinder their ability to provide optimal care to patients and can lead to errors and adverse outcomes. Additionally, nurses may not always receive the support they need from their supervisors or colleagues, which can further exacerbate the challenges they face in their day-to-day work [9].

Furthermore, the complexity of healthcare systems and regulations can pose challenges for nurses in care settings. Nurses are required to adhere to strict protocols and guidelines to ensure patient safety and quality of care. However, these regulations can be overwhelming and time-consuming, taking nurses away from direct patient care. Additionally, healthcare systems are constantly evolving, with new technologies and treatments being introduced regularly. Nurses must stay up-to-date with these changes, which can be challenging in an already demanding work environment [5].

Communication breakdowns are another common challenge in nursing care settings. Effective communication is essential for providing safe and efficient patient care, but nurses may face barriers such as language barriers, cultural differences, and conflicting priorities among healthcare team members. These communication breakdowns can

lead to misunderstandings, errors, and delays in care, putting patients at risk [21].

Nursing care settings face numerous implementation challenges that can impact the quality of care provided to patients. Addressing these challenges requires a multifaceted approach, including increasing staffing levels, providing adequate resources and support, streamlining healthcare systems and regulations, and improving communication among healthcare team members. By addressing these challenges, nurses can provide better care to patients and improve outcomes in nursing care settings [11].

### **Impact of Pharmacogenomics on Patient Safety:**

Pharmacogenomics, also known as pharmacogenetics, is a field of study that focuses on how an individual's genetic makeup influences their response to drugs. By analyzing a patient's genetic information, healthcare providers can tailor treatment plans to maximize efficacy and minimize adverse effects. This personalized approach to medicine has the potential to revolutionize patient care and improve outcomes, particularly in the realm of patient safety [17].

One of the key ways in which pharmacogenomics impacts patient safety is through the prevention of adverse drug reactions (ADRs). ADRs are a significant cause of morbidity and mortality in healthcare settings, with estimates suggesting that they account for up to 5% of hospital admissions and 6.5% of all hospitalizations. By identifying genetic variants that predispose individuals to ADRs, healthcare providers can avoid prescribing medications that are likely to cause harm, thus reducing the risk of adverse events and improving patient safety [18].

For example, certain genetic variations in the enzyme CYP2D6 are known to affect the metabolism of a wide range of medications, including antidepressants, antipsychotics, and painkillers. Patients who are poor metabolizers of CYP2D6 may be at increased risk of experiencing toxic side effects from these drugs, while ultra-rapid metabolizers may not achieve therapeutic levels of the medication. By screening for CYP2D6 variants before prescribing these medications, healthcare providers can adjust dosages or choose alternative treatments to ensure patient safety [19]. In addition to preventing ADRs, pharmacogenomics can also enhance the efficacy of drug therapy by identifying the most appropriate medications for each individual. For example, genetic testing can reveal whether a patient is likely to respond well to a particular drug or whether they are at risk of treatment failure due to genetic factors. By tailoring treatment plans to a patient's



genetic profile, healthcare providers can optimize outcomes and reduce the likelihood of treatment resistance or relapse [20].

Furthermore, pharmacogenomics can help to streamline the medication management process by guiding dosing adjustments and monitoring strategies. For example, patients who are poor metabolizers of certain drugs may require lower doses to achieve therapeutic effects, while ultra-rapid metabolizers may need higher doses to avoid treatment failure. By incorporating genetic information into medication dosing algorithms, healthcare providers can reduce the risk of under- or overdosing and ensure that patients receive the right amount of medication for their individual needs [21].

Overall, the impact of pharmacogenomics on patient safety is profound and far-reaching. By leveraging genetic information to guide treatment decisions, healthcare providers can minimize the risk of adverse drug reactions, enhance treatment efficacy, and optimize medication management strategies. As the field of pharmacogenomics continues to advance, it holds great promise for improving patient outcomes and revolutionizing the practice of personalized medicine [22].

#### **Future Directions and Innovations in Personalized Medication Therapy:**

Personalized medication therapy, also known as precision medicine, is a rapidly evolving field that aims to tailor medical treatment to an individual's unique genetic makeup, lifestyle, and environment. By taking into account these factors, healthcare providers can optimize the effectiveness of medications and minimize potential side effects. As technology advances and our understanding of genetics deepens, the future of personalized medication therapy holds great promise for improving patient outcomes and revolutionizing the way we approach healthcare [23].

One of the key future directions in personalized medication therapy is the use of pharmacogenomics, which involves studying how an individual's genetic variations affect their response to medications. By analyzing a patient's genetic profile, healthcare providers can predict how they will metabolize certain drugs and adjust dosages accordingly. This can help avoid adverse drug reactions and ensure that patients receive the most effective treatment for their specific genetic makeup [24].

Another exciting innovation in personalized medication therapy is the use of digital health technologies, such as wearable devices and mobile apps, to monitor patients' health in real-time. These tools can track vital signs, medication adherence,

and other health metrics, allowing healthcare providers to make more informed decisions about treatment plans. By incorporating these technologies into personalized medication therapy, patients can receive more proactive and personalized care, leading to better health outcomes [25].

In addition to pharmacogenomics and digital health technologies, the future of personalized medication therapy also holds potential for the development of targeted therapies based on a patient's specific disease characteristics. For example, researchers are exploring the use of gene editing technologies, such as CRISPR-Cas9, to modify a patient's genetic code and treat genetic disorders at the source. This approach could revolutionize the treatment of diseases such as cystic fibrosis, sickle cell anemia, and certain types of cancer [26].

Furthermore, advancements in artificial intelligence and machine learning are poised to play a significant role in the future of personalized medication therapy. These technologies can analyze vast amounts of data, including genetic information, medical records, and clinical trial results, to identify patterns and predict how patients will respond to different treatments. By harnessing the power of AI and machine learning, healthcare providers can make more precise treatment decisions and tailor medication therapy to each individual's unique needs [27].

Overall, the future of personalized medication therapy is bright, with exciting innovations on the horizon that have the potential to transform healthcare as we know it. By leveraging pharmacogenomics, digital health technologies, targeted therapies, and artificial intelligence, healthcare providers can deliver more personalized and effective treatments to patients, ultimately improving outcomes and quality of life. As research continues to advance in this field, we can expect to see even more groundbreaking developments that will revolutionize the way we approach medication therapy and personalized healthcare [28].

#### **Case Studies and Success Stories in Pharmacogenomics Integration:**

Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has gained significant attention in recent years. By integrating pharmacogenomics into clinical practice, healthcare providers can personalize treatment plans for patients, leading to improved outcomes and reduced adverse drug reactions [29].

One of the most well-known success stories in pharmacogenomics integration is the case of St.

Jude Children's Research Hospital in Memphis, Tennessee. St. Jude implemented a pharmacogenomics program for pediatric cancer patients, using genetic testing to identify which drugs would be most effective and which ones should be avoided based on the patient's genetic profile. By tailoring treatment plans to each individual patient, St. Jude was able to improve survival rates and reduce the risk of toxic side effects [30].

Another notable case study is the Mayo Clinic's Center for Individualized Medicine, which has been at the forefront of integrating pharmacogenomics into clinical practice. The Mayo Clinic uses genetic testing to guide treatment decisions for a wide range of conditions, including cardiovascular disease, cancer, and psychiatric disorders. By incorporating pharmacogenomics into routine care, the Mayo Clinic has been able to optimize drug therapy for patients, resulting in better outcomes and reduced healthcare costs [31]. In addition to these institutional success stories, there are also many individual cases where pharmacogenomics has made a significant impact on patient care. For example, a patient with depression who was not responding to traditional antidepressants underwent genetic testing that revealed they had a genetic variant that made them less likely to benefit from certain medications. By switching to a different antidepressant that was more compatible with their genetic profile, the patient experienced a dramatic improvement in their symptoms [32].

Overall, the integration of pharmacogenomics into clinical practice has the potential to revolutionize healthcare by allowing for more personalized and effective treatment plans. As more healthcare providers adopt pharmacogenomics testing and incorporate the results into their decision-making process, we can expect to see even more success stories like those mentioned above. By leveraging the power of genetics to inform drug therapy, we can improve patient outcomes, reduce adverse drug reactions, and ultimately provide more precise and individualized care [33].

### Conclusion:

In conclusion, pharmacogenomics is playing an increasingly important role in personalized medication therapy for patients in nursing care. By analyzing a patient's genetic information, nurses can identify the most effective and safe treatment options for each individual patient. This personalized approach not only improves patient outcomes and reduces the risk of adverse drug reactions, but also has the potential to reduce healthcare costs. As pharmacogenomics continues

to advance, it is essential for nurses to stay informed and educated on how to incorporate this valuable tool into their practice to provide the best possible care for their patients.

### References:

1. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther.* 2014;95(4):376-382.
2. Relling MV, Evans WE. Pharmacogenomics in the clinic. *Nature.* 2015;526(7573):343-350.
3. Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther.* 2015;98(2):127-134.
4. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte—an update of guidelines. *Clin Pharmacol Ther.* 2011;89(5):662-673.
5. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. *Clin Pharmacol Ther.* 2012;91(3):450-458.
6. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. *Clin Pharmacol Ther.* 2014;95(4):423-431.
7. Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. *Clin Pharmacol Ther.* 2014;96(4):423-428.
8. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. *Clin Pharmacol Ther.* 2013;94(3):317-323.
9. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. *Clin Pharmacol Ther.* 2012;92(2):235-242.
10. Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. *Pharmacogenomics J.* 2006;6(3):162-165.
11. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther.* 2011;89(3):464-467.

12. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. *Clin Pharmacol Ther.* 2013;94(2):214-217.
13. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. *Clin Pharmacol Ther.* 2017;102(4):688-700.
14. Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. *Pharmacogenomics J.* 2013;13(6):481-483.
15. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. *Pharmacogenomics.* 2014;15(5):655-665.
16. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. *Clin Pharmacol Ther.* 2014;95(4):423-431.
17. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther.* 2012;92(4):414-417.
18. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther.* 2011;89(3):464-467.
19. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. *Clin Pharmacol Ther.* 2013;94(2):214-217.
20. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. *Clin Pharmacol Ther.* 2017;102(4):688-700.
21. Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. *Pharmacogenomics J.* 2013;13(6):481-483.
22. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. *Pharmacogenomics.* 2014;15(5):655-665.
23. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. *Clin Pharmacol Ther.* 2014;95(4):423-431.
24. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther.* 2012;92(4):414-417.
25. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther.* 2011;89(3):464-467.
26. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. *Clin Pharmacol Ther.* 2013;94(2):214-217.
27. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. *Clin Pharmacol Ther.* 2017;102(4):688-700.
28. Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. *Pharmacogenomics J.* 2013;13(6):481-483.
29. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. *Pharmacogenomics.* 2014;15(5):655-665.
30. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. *Clin Pharmacol Ther.* 2014;95(4):423-431.
31. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther.* 2012;92(4):414-417.
32. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. *Clin Pharmacol Ther.* 2011;89(3):464-467.
33. Gottesman O, Scott SA, Ellis SB, et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. *Clin Pharmacol Ther.* 2013;94(2):214-217.